PREPARED BY: JEGAN. S. NADAR
RHEUMATOID ARTHRITIS
RHEUMATOID ARTHRITIS
 Rheumatoid arthritis (RA) is a chronic autoimmune disease.
 It causes joints to swell and can result in pain, stiffness, and progressive loss
of function.
 RA often affects pairs of joints (both hands, both feet, etc) and can affect
more than one joint, including the small joints in the wrists and hands.
 Over time, other joints can be affected such as shoulders, elbows, knees, feet,
and ankles. Jegan
 Over time, the inflammation of RA can cause damage to the joints.
 In some patients, this may lead to permanent joint damage.
 As this joint damage progresses, in severe cases, it can cause deformity of the
joints and loss of function.
 It may begin to interfere with daily activities, making them more difficult and
painful to do
 RA often begins in middle age, but can start at any age.
 RA affects 2 to 3 times as many women than men.
Jegan
Jegan
PATHOPHYSIOLOGY
 Rheumatoid arthritis is autoimmune disorder in which Immune system
identifies the synovial membrane as "foreign“ and begins attacking it
 With long-term or intensive exposure to the antigen, normal antibodies
become auto-antibodies that target self-antigens in the synovial
membrane.
 Once the antigen or immune complex reaches the synovial membrane .The
antigen presenting cell deals with it. Jegan
 First, the Antigen Presenting Cell usually a macrophage in synovium engulfs
the antigen.
 Enzymes (peroxides) inside the APC break down the antigen into smaller
particles
 The processed antigens are transported to the surface of the APC
 Antigen is now presented to T-cells (CD4 cells ie. T-helper cell ) or CD8
(cytotoxic T cells) which the T-cell receptor (TCR) recognizes and binds to.
Jegan
 Once the T-cell binds to the Antigen it becomes activated, the APC then
secrete cytokines like
 Interleukin-1 (IL-1)
 Interferon-alpha (IFN-a)
 Interferon-gamma (IFN-g)
 Tumor necrosis factor (TNF)
 APC also Secretes Lysozymes, Elastases and Collagenases these enzymes
cause cartilage breakdown.
Jegan
 On exposure to IL-1, synoviocytes proliferate and produce following
factors
 Interleukin-6 (IL-6)
 Prostaglandin's (e.g. , PGE2) , and platelet-activating factor, which are
involved in the pain mechanism.
 Matrix Metalloproteases that cause activation of collagenase, an enzyme
required for cartilage breakdown.
Jegan
SYMPTOMS
 Joint pain
 Joint tenderness
 Joint swelling
 Joint redness
 Joint warmth
 Joint stiffness
 Many joints affected (polyarthritis)
 Joint deformity
 Both sides of the body affected (symmetric) Jegan
DIAGNOSIS
 Physical examination
 Blood test
 Antibody test
 ESR
 X-Ray
 MRI
Jegan
TREATMENT
 NSAIDs
 Steroids.
 Disease-modifying antirheumatic drugs (DMARDs)
 Surgery
 Synovectomy
 Tendon repair
 Total joint replacement Jegan
Thank You

Pathophysiology of Rheumatoid arthritis

  • 1.
    PREPARED BY: JEGAN.S. NADAR RHEUMATOID ARTHRITIS
  • 2.
    RHEUMATOID ARTHRITIS  Rheumatoidarthritis (RA) is a chronic autoimmune disease.  It causes joints to swell and can result in pain, stiffness, and progressive loss of function.  RA often affects pairs of joints (both hands, both feet, etc) and can affect more than one joint, including the small joints in the wrists and hands.  Over time, other joints can be affected such as shoulders, elbows, knees, feet, and ankles. Jegan
  • 3.
     Over time,the inflammation of RA can cause damage to the joints.  In some patients, this may lead to permanent joint damage.  As this joint damage progresses, in severe cases, it can cause deformity of the joints and loss of function.  It may begin to interfere with daily activities, making them more difficult and painful to do  RA often begins in middle age, but can start at any age.  RA affects 2 to 3 times as many women than men. Jegan
  • 4.
  • 5.
    PATHOPHYSIOLOGY  Rheumatoid arthritisis autoimmune disorder in which Immune system identifies the synovial membrane as "foreign“ and begins attacking it  With long-term or intensive exposure to the antigen, normal antibodies become auto-antibodies that target self-antigens in the synovial membrane.  Once the antigen or immune complex reaches the synovial membrane .The antigen presenting cell deals with it. Jegan
  • 6.
     First, theAntigen Presenting Cell usually a macrophage in synovium engulfs the antigen.  Enzymes (peroxides) inside the APC break down the antigen into smaller particles  The processed antigens are transported to the surface of the APC  Antigen is now presented to T-cells (CD4 cells ie. T-helper cell ) or CD8 (cytotoxic T cells) which the T-cell receptor (TCR) recognizes and binds to. Jegan
  • 7.
     Once theT-cell binds to the Antigen it becomes activated, the APC then secrete cytokines like  Interleukin-1 (IL-1)  Interferon-alpha (IFN-a)  Interferon-gamma (IFN-g)  Tumor necrosis factor (TNF)  APC also Secretes Lysozymes, Elastases and Collagenases these enzymes cause cartilage breakdown. Jegan
  • 8.
     On exposureto IL-1, synoviocytes proliferate and produce following factors  Interleukin-6 (IL-6)  Prostaglandin's (e.g. , PGE2) , and platelet-activating factor, which are involved in the pain mechanism.  Matrix Metalloproteases that cause activation of collagenase, an enzyme required for cartilage breakdown. Jegan
  • 9.
    SYMPTOMS  Joint pain Joint tenderness  Joint swelling  Joint redness  Joint warmth  Joint stiffness  Many joints affected (polyarthritis)  Joint deformity  Both sides of the body affected (symmetric) Jegan
  • 10.
    DIAGNOSIS  Physical examination Blood test  Antibody test  ESR  X-Ray  MRI Jegan
  • 11.
    TREATMENT  NSAIDs  Steroids. Disease-modifying antirheumatic drugs (DMARDs)  Surgery  Synovectomy  Tendon repair  Total joint replacement Jegan
  • 12.